Advertisement

Breast Cancer Research and Treatment

, Volume 4, Issue 3, pp 189–193 | Cite as

Epidermal growth factor receptors in human breast cancer

  • Rolando Pérez
  • María Pascual
  • Amparo Macías
  • Agustín Lage
Report

Summary

The capacity for specific binding of125I-epidermal growth factor (EGF) was studied in crude membrane fractions from 95 human breast carcinomas. About 42% of the samples showed saturable, high affinity, specific binding of EGF. In 21% of the tumors we were able to demostrate high (above 10 fmoles/mg protein) binding capacity. Moreover, high EGF receptor values were associated with a low content of estradiol receptor. These studies are related to the definition of new biochemical markers in human breast cancer.

Keywords

estrogen receptor breast cancer EGF receptor growth factors 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    McGuire WL: Hormone Receptors and Breast Cancer. Raven Press, New York, 1978Google Scholar
  2. 2.
    Knight WA, Livingston RB, Gregory EJ: Estrogen receptors as independent prognostic factors for early recurrence in breast cancer. Cancer Res 37:4669–4671, 1977Google Scholar
  3. 3.
    Hähnel R, Woodings T, Vivan AB: Prognostic value of estrogen receptor in primary breast cancer. Cancer 44:671–675, 1979PubMedGoogle Scholar
  4. 4.
    Furmanski P, Saunders DE, Brooks SC, Rich MA: The prognostic value of estrogen determinations in patients with primary breast cancer: an update. Cancer 46:2794–2796, 1980PubMedGoogle Scholar
  5. 5.
    Pascual MR, Macías A, Moreno L, Lage A: Factors associated with prognosis in human breast cancer. III. Estradiol receptors and short-term relapse (submitted to Neoplasma)Google Scholar
  6. 6.
    Pichon MF, Pailud C, Brunet M, Milgrom E: Relationship of presence of progesterone receptors to prognosis in early breast cancer. Cancer Res 40:3357–3360, 1980Google Scholar
  7. 7.
    Turkington RW: Stimulation of mammary carcinoma cell proliferation by epithelial growth factor in vitro. Cancer Res 29:1457–1458, 1969PubMedGoogle Scholar
  8. 8.
    Tonelli QJ, Sorof S: Epidermal growth factor requirement for development of cultured mammary gland. Nature 285:250–252, 1980PubMedGoogle Scholar
  9. 9.
    Osborne CK, Hamilton B, Titus G, Livingston RB: Epidermal growth factor stimulation of human breast cancer cells in culture. Cancer Res 40:2361–2366, 1980Google Scholar
  10. 10.
    Osborne CK, Hamilton B, Nover M: Receptor binding and processing of epidermal growth factor (EGF) by human breast cancer cells. Proc Am Assoc Cancer Res 22:4, 1981Google Scholar
  11. 11.
    Imai Y, Leung CKH, Friesen HG, Shiu RPC: Epidermal growth factor receptors and effect of epidermal growth factor on growth of human breast cancer cells in long-term tissue culture. Cancer Res 42:4394–4398, 1982Google Scholar
  12. 12.
    Savage CR, Cohen S: Epidermal growth factor and a new derivative. Rapid isolation procedures and biological and chemical characterization. J Biol Chem 247:7609–7611, 1972Google Scholar
  13. 13.
    Hunter WM, Greenwood FC: Preparation of iodine-131 labelled human growth hormone of high specific activity. Nature 194:495–496, 1962PubMedGoogle Scholar
  14. 14.
    MH Harmes (ed): UICC-TNM Classifications of Malignant Tumors. UICC, Geneve, 1978, 49 ppGoogle Scholar
  15. 15.
    EORTC Breast Cancer Cooperative Group: Standards for the assessment of estrogen receptor in human breast cancer. Eur J Cancer 9:379–381, 1973Google Scholar
  16. 16.
    Scatchard G: The attraction of proteins for small molecules and ions. Ann NY Acad Sci 31:660–672, 1969Google Scholar
  17. 17.
    Kendall MG: Rank Correlation Methods. Griffin, London, 1948Google Scholar
  18. 18.
    O'Keefe E, Hollenberg MD, Cuatrecasas P: Epidermal growth factor. Characteristics of specific binding in membranes from liver, placenta, and other target tissues. Arch Biochem Biophys 164:518–526, 1974PubMedGoogle Scholar
  19. 19.
    Fitzpatrick SL, Brightwell JR, Wittliff JL, Schultz GS: Correlation of epidermal growth factor receptors with estrogen and progestin receptor concentrations in breast cancer. Fed Proc 41:1163, 1982Google Scholar
  20. 20.
    Pérez R, Chambard JC, Van Obberghen-Schilling E, Franchi A, Pouyssegur J: Emergence of hamster fibroblast tumors in nude mice: evidence for in vivo selection leading to loss of growth factor requirement. J Cell Physiol 109:387–396, 1981PubMedGoogle Scholar
  21. 21.
    Pérez R, Franchi A, Deys BF, Pouyssegur J: Evidence that hamster fibroblast tumors emerge in nude mice through the process of two in vivo selections leading to growth factor ‘relaxation’ and immune resistance. Int J Cancer 29:309–314, 1982PubMedGoogle Scholar
  22. 22.
    Todaro GJ, De Larco JE, Nissley SP, Rechler NM: MSA and EGF receptors on sarcoma virus transformed cells and human fibrosarcoma cells in culture. Nature 267:526–528, 1977PubMedGoogle Scholar
  23. 23.
    De Larco JE, Todaro GJ: Growth factors from murine sarcoma virus-transformed cells. Proc Natl Acad Sci USA 75:4001–4005, 1978PubMedGoogle Scholar
  24. 24.
    Macías A, Pascual MR, Pérez R, Lage A: Factors associated with prognosis in human breast cancer. IV. Progesterone receptors and clinical factors (submitted to Neoplasma)Google Scholar

Copyright information

© Martinus Nijhoff Publishers 1984

Authors and Affiliations

  • Rolando Pérez
    • 1
  • María Pascual
    • 1
  • Amparo Macías
    • 1
  • Agustín Lage
    • 1
  1. 1.Instituto de Oncología y RadiobiologíaHabana 4Cuba

Personalised recommendations